Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization


29 Sep 2019


Poster Display session 2


Tumour Site

Hepatobiliary Cancers


Xiaolu Ma


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


X. Ma1, X. Qu2, W. Yang1, H. Wang1, B. Wang1, M. Shen1, Y. Zhou1, C.Y. Zhang1, Y. Sun3, J. Chen3, B. Hu3, Z. Gong3, X. Zhang3, B. Pan1, J. Zhou3, J. Fan3, X. Yang3, W. Guo1

Author affiliations

  • 1 Laboratory Medicine, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 2 Intervention Radiology, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 3 Liver Surgery, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3641


Soluble programmed death-ligand 1 (sPD-L1) is associated with hepatocellular carcinoma (HCC) prognosis after resection or radiotherapy. However, its value in patients who received transcatheter arterial chemoembolization (TACE) remains unclear. The present study aimed to determine the prognostic significance of sPD-L1 in TACE subgroup.


114 HCC patients with hepatitis B virus (HBV)-background who received TACE from 2012 to 2013 were recruited. sPD-L1 levels were determined by enzyme-linked immunosorbent assay. We evaluated prognoses according to mRESIST criteria and analyzed prognostic values by Cox regression and Kaplan-Meier analysis. We further evaluated correlations between sPD-L1 and systemic inflammation index (SII), soluble interleukin-2 receptor (sIL-2R), IL-10, hepatitis B virus (HBV)-DNA loads, and C-reactive protein.


Significantly elevated sPD-L1 levels were found in patients who developed HCC progression (P = 0.002) and death (P < 0.001). Patients with higher pre-treatment sPD-L1 levels had a significantly shorter time to progression (10.50 vs. 18.25 months, P = 0.001) and decreased overall survival (16.50 vs. 28.50 months, P = 0.003). In low-recurrence-risk subgroups, sPD-L1 levels retained prognostic value (P < 0.050). Importantly, multivariate regression confirmed that pre-treatment sPD-L1 level was an independent predictor for both progression [hazard ratio (HR) 1.82; P = 0.032] and survival (HR 1.84; P = 0.009). Moreover, sPD-L1 levels positively correlated with SII (r = 0.284, P = 0.002), sIL-2R (r = 0.239, P = 0.010), IL-10 (r = 0.283, P = 0.002), HBV-DNA loads (r = 0.229, P = 0.014), and CRP (r = 0.237, P = 0.011).


sPD-L1 level is a prognostic indicator of poor outcomes after TACE. High sPD-L1 indicated increased immune activation in an immunosuppressive environment that hindered anti-tumor response activity. Lowering sPD-L1 levels may provide a novel avenue for preventing HCC progression post-TACE.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


The National Natural Science Foundation of China (87172263 and 81572064) and Key Developing Disciplines of Shanghai Municipal Commission of Health and Family Planning (2015ZB0201).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.